IO-resistant sqNSCLC

Oncology

6 drugs in development·2 companies·1 clinical trial

Drug Pipeline by Phase

Phase 3(6)

Drug	Company
control	Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) (TAK)
control	TAKEDA PHARMACEUTICAL CO LTD (TKPHF)
control arm	Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) (TAK)
control arm	TAKEDA PHARMACEUTICAL CO LTD (TKPHF)
tak-928	Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) (TAK)
tak-928	TAKEDA PHARMACEUTICAL CO LTD (TKPHF)

BioSniper tracks 6 drugs in development for IO-resistant sqNSCLC across 2 companies.

There are 1 clinical trial targeting IO-resistant sqNSCLC tracked by BioSniper.

Full trial data, competitive analysis, and AI-powered pipeline tracking.